Related Experiment Video
Updated: Jul 24, 2026
08:19
Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
Published on: June 1, 2012
A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration
S J Updike1, M C Shults, B J Gilligan
1Department of Medicine, University of Wisconsin Center for Health Sciences, Madison, USA. sjupdike@facstaff.wisc.edu
Diabetes Care
|June 27, 2000
Summary
New continuous glucose sensors show stable performance for up to 5 months in dogs. Improved sensor technology offers a promising, painless method for long-term blood glucose monitoring.
Area of Science:
- Biomedical Engineering
- Medical Devices
- Diabetes Technology
Background:
- Continuous glucose monitoring (CGM) is crucial for diabetes management.
- Existing CGM technologies face limitations in longevity and accuracy.
- Novel sensor designs are needed to improve long-term glucose monitoring.
Purpose of the Study:
- To evaluate the performance of two types of continuous glucose sensor implants in a canine model.
- Assess key parameters including lifetime, response time, linearity, glucose range, and calibration stability.
- Compare earlier-stage technology with improved later-stage sensor designs.
Main Methods:
- Enzyme electrode-based glucose sensors with radio transmitters were bench-tested and implanted subcutaneously in dogs.
- Sensor performance was evaluated in vivo using induced hyperglycemic and hypoglycemic conditions.
- Glucose levels were manipulated across the clinical range (2.2–38.9 mmol/l) via insulin and glucose infusions.
- Reference blood glucose samples were analyzed in a clinical laboratory, with data assessed using linear regression and error grid analysis.
Main Results:
- Both sensor types demonstrated response times of 4-7 minutes.
- Earlier-stage sensors showed limited linearity (up to 22 mmol/l) and a maximum lifetime of 94 days.
- Improved sensors, incorporating bioprotective and angiogenic membranes, exhibited linearity across the full clinical range (2.2–38.9 mmol/l).
- Later-stage sensors achieved a best-case recalibration interval of 20 days and a lifetime exceeding 160 days.
Conclusions:
- Stable, clinically useful continuous glucose sensor performance was achieved as early as 7 days post-implantation.
- The evaluated subcutaneous glucose sensors show promise for continuous, long-term, and painless blood glucose monitoring.
- Sensors utilizing materials that promote angiogenesis demonstrated enhanced dynamic measurement range, longevity, and calibration stability.
Related Concept Videos
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...